Chinese quality control indices for standardized diagnosis and treatment of gastric cancer(2022 edition)

Gastric cancer is one of the most common malignancies of the digestive system,and the number of deaths continues to increase.The standardized management of the diagnosis and treatment of gastric cancer is challenging due to the great differences in the diagnosis and treatment of gastric cancer in different regions.The Gastric Cancer Expert Committee of the National Cancer Quality Control Center(NCQCC)identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of gastric cancer.The Gastric Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization,uniformity,and normalization of gastric cancer diagnosis and treatment,which ultimately improved the survival rate and quality of life of gastric cancer patients.A panel of experts with gastrointestinal cancer surgery,gastrointestinal cancer medicine,medical imaging,pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of gastric cancer.The authors then utilized a modified Delphi approach to generate consensus recommendations.

Effect of standard heat treatment on microstructure and properties of borided Inconel 718

Boronizing was applied to Inconel 718. In order to obtain the optimal combination of strength and ductility, the borided Inconel 718 was subjected to standard heat treatment. This consists of solution treatment and then a two-step aging treatment. The borided layer is composed of the compound layer and the boron diffusion zone. Because of the superior hardness of borides, the borided Inconel 718 exhibits a significant reduction in its wear rate and relatively low coefficient of friction （COF） compared with the unborided Inconel 718. The standard heat treatment efficiently promotes the diffusion of boron into the interior of the material and the generation of new borides （Fe2B, CrB）. The borided layer with standard heat treatment shows much better wear resistance due to the thicker borided layer （313.76 μm）.

Transjugular intrahepatic portosystemic shunt for esophagogastric variceal bleeding in patients with hepatocellular carcinoma and portal vein tumor thrombus

BACKGROUND Whether hepatocellular carcinoma(HCC)with portal vein tumor thrombus(PVTT)and acute esophagogastric variceal bleeding(EGVB)can improve the success rate of endoscopic hemostasis and overall survival(OS)from transjugular intrahepatic portosystemic shunt(TIPS)remains controversial.AIM To compare the clinical outcomes between TIPS and standard treatment for such HCC patients.METHODS This monocenter,retrospective cohort study included patients diagnosed as HCC with PVTT and upper gastrointestinal bleeding.Patients were grouped by the treatment(TIPS or standard conservative treatment).The success rate of en-doscopic hemostasis,OS,rebleeding rates,and main causes of death were ana-lyzed.RESULTS Between July 2015 and September 2021,a total of 77 patients(29 with TIPS and 48 with standard treatment)were included.The success rate of endoscopic hemostasis was 96.6%in the TIPS group and 95.8%in the standard treatment group.All the 29 patients in TIPS group successful underwent TIPS procedure and had a better OS compared with standard treatment within the first 160 days after treatment(68 days vs 43 days,P=0.022),but shorter OS after 160 days(298 days vs 472 days, P = 0.022). Cheng’s Classification of PVTT, total bilirubin and Child-Pugh class wereindependently negative associated with OS (all P < 0.05). The main causes of death were liver failure or hepaticencephalopathy (75.9%) in the TIPS group and rebleeding (68.8%) in the standard treatment.CONCLUSIONTIPS could reduce the risk of early death due to rebleeding and prolong short-term survival in HCC patients withPVTT and acute EGVB, which deserves further investigation.

Autoimmune hepatitis: standard treatment and systematic review of alternative treatments

Autoimmune hepatitis is a rare chronic inflammatory liver disease,affecting all ages,characterised by elevated transaminase and immunoglobulin G levels,positive autoantibodies,interface hepatitis at liver histology and good response to immunosuppressive treatment. If untreated,it has a poor prognosis. The aim of this review is to summarize the evidence for standard treatment and to provide a systematic review on alternative treatments for adults and children. Standard treatment is based on steroids and azathioprine,and leads to disease remission in 80%-90% of patients. Alternative first line treatment has been attempted with budesonide or cyclosporine,but their superiority compared to standard treatment remains to be demonstrated. Second-line treatments are needed for patients not responding or intolerant to standard treatment. No randomized controlled trials have been performed for second-line options. Mycophenolate mofetil is the most widely used second-line drug,and has good efficacy particularly for patients intolerant to azathioprine,but has the major disadvantage of being teratogenic. Only few and heterogeneous data on cyclosporine,tacrolimus,everolimus and sirolimus are available. More recently,experience with the anti-tumour necrosis factoralpha infliximab and the anti-CD20 rituximab has been published,with ambivalent results; these agents may have severe side-effects and their use should be restricted to specialized centres. Clinical trials with new therapeutic options are ongoing.

Standard heat treatment effects on TLP bonded IN-738LC superalloy using BNi-9 filler:An approach to make an ideal joint

The present research is focused on the effects of standard heat treatment on the microstructure and mechanical properties of diffusion brazed IN-738 LC superalloy.Three distinct heat treatment cycles of full solution annealing,partial solution annealing,and aging treatment were applied to the bonded specimens,sequentially.The results reveal that bonding at 1120℃for 5 min leads to incomplete isothermal solidification and formation of eutectic phases including Ni-and Cr-rich borides in the joint centerline.Increasing the holding time to 45 min leads to the full isothermal solidification and formation of a nickel proeutectic solid-solution phase(γ)in the joints.The standard heat treatment of isothermally solidified and non-isothermally solidified specimens results in the complete elimination of the boride phases in the diffusion-affected zone and also the formation ofγ’precipitates in the isothermally solidified zone.However,discontinuously re-solidified products are observed in joint district in the non-isothermally solidified sample.The highest shear strength(~801 MPa)is achieved for isothermally solidified specimen after standard heat treatment;this strength is approximately 99%that of the substrate material.

Quality control indices for standardized diagnosis and treatment of esophageal cancer in China (2022 edition)

Esophageal cancer(EC)is particularly common in China.With the continuing progress of multi-disciplinary therapy including early screening,minimally invasive techniques,radiotherapy and chemotherapy,the 5-year survival of EC has been improved in China.However,there are considerable disparities in the diagnosis and treatment quality among different regions.The Esophageal Cancer Expert Committee of the National Cancer Quality Control Center(NCQCC)considers a set of authoritative quality control standards as an opportunity to eliminate the disparities and improve the overall survival and quality of life of EC.To further promote the quality control for standardized diagnosis and treatment of EC,the National Cancer Center commissioned the Esophageal Cancer Quality Control Expert Committee to draft and formulate the Chinese Quality Control Indices for Standardized Diagnosis and Treatment of Esophageal Cancer(2022 edition).The Indices includes 21 items that cover all key areas in the diagnosis and treatment of esophageal cancer,such as medical oncology,radiation oncology,endoscopy,and pathology.

Chinese quality control indices for standardized diagnosis and treatment of renal cancer(2022 edition)

Renal cancer is one of the most common malignancies of the urinary system,and the number of deaths continues to increase.The standardized management of the diagnosis and treatment of renal cancer is challenging due to the great differences in the diagnosis and treatment of renal cancer in different regions.The Renal Cancer Expert Committee of the National Cancer Quality Control Center(NCQCC)identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of renal cancer.The Renal Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization,uniformity,and normalization of renal cancer diagnosis and treatment,which ultimately improved the survival rate and quality of life of renal cancer patients.A panel of experts with renal cancer surgery,renal cancer medicine,medical imaging,pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of renal cancer.The Indices includes 20 items that cover all key areas in the diagnosis and treatment of renal cancer,such as standard diagnosis,surgery treatment,systemic treatment,and prognostic evaluation.

Developement of processes for nutrient removal from wastewater

This review focuses on techniques for achieving very low concentration of TN and TP in water.The 1970 Clean Water Act in the US and the Urban Waste Water Treatment Directive in Europe now provide the benchmark standards for TN and TP levels.Arden and Lockett discovered activated sludge in the 1910’s.Since then,many improvements have been made to the biological treatment process to provide various configurations that have the ability to deliver effluent concentrations between 6-8mg TN/L and 0.5-1.0mg TP/L,without external carbon addition.Typically,however,additional advanced nutrient removal technologies are used in tertiary treatment to meet more stringent effluent quality requirements.One advanced technology that has been successfully implemented in the US is denitrifying filters.For TP removal,tests showed that the BlueP RO and CoM ag systems both reliably met an effluent target as low as 0.04 mg TP/L.However,the establishment of stringent TN and TP effluent limits will dramatically increase the capital and operational costs of wastewater treatment plants.A more promising nutrient capturing process is based on the assimilation of nutrients(both N and P)during heterotrophic growth which uses a carbon source for energy.Laboratory trials of the single step process by Reach Green suggest that concentrations as low as 0.5 mg TN/L and 0.02mg TP/L are readily achievable.

Current status of immunotherapy in gastric cancer

Gastric cancer is one of the most common cancer with high mortality and morbilidity in East Asia,especially in China.In recent year,new treatment strategies for gastric cancer have developed.Immune check point inhibitors(ICIs)have been detected as a new standard treatment in Gastric cancer,which helped to improve the prognosis of patients with gastric cancer.Attempts to combine immunotherapy have become one of the research focuses.In this article,application of immunotherapy in neoadjuvant therapy and translational treatment of gastric cnacer are reviewed.Which is expected to be a reference for comprehensive treatment plan of accurate treatment methods for gastric cancer patients.In order to provide experiences and reference to develop individualized treatment of gastric cancer in clinical practice.

Towards efficiency in rare disease research： what is distinctive and important？

Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide.Over the past decades, efforts from researchers, clinicians, and pharmaceutical industries have been focused on both the diagnosis and therapy of rare diseases. However, because of the lack of data and medical records for individual rare diseases and the high cost of orphan drug development, only limited progress has been achieved. In recent years, the rapid development of next-generation sequencing(NGS)-based technologies, as well as the popularity of precision medicine has facilitated a better understanding of rare diseases and their molecular etiology. As a result, molecular subclassification can be identified within each disease more clearly, significantly improving diagnostic accuracy. However, providing appropriate care for patients with rare diseases is still an enormous challenge. In this review, we provide a brief introduction to the challenges of rare disease research and make suggestions on where and how our efforts should be focused.